ContraFect Corporation to Announce Fourth Quarter and Full Year 2015 Results on March 15, 2016
March 08, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 08, 2016) -
ContraFect Corporation
(NASDAQ: CFRX)
(NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and...
ContraFect to Present at 18th Annual BIO CEO and Investor Conference
February 02, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - February 02, 2016) -
ContraFect Corporation
(NASDAQ: CFRX)
(NASDAQ: CFRXW), a biotechnology company focused on the discovery and...
(UPDATED) UNITY Consortium Established to Support Immunizations for Today's Teens and Young Adults
August 28, 2015 14:04 ET
|
UNITY Consortium
NEWTOWN, Pa., Aug. 28, 2015 (GLOBE NEWSWIRE) -- UNITY Consortium has launched as a coalition that brings together a wide range of organizations with a singular focus on improving adolescent and young...
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
April 07, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
Get Added Protection Against H3N2 with A.Vogel's Clinically Proven Echinaforce(R)
February 03, 2015 10:01 ET
|
Bioforce Canada
MONTREAL, Feb. 3, 2015 (GLOBE NEWSWIRE) -- A recent study confirms that the 2014-2015 flu vaccine offers little or no protection from this year's predominant influenza strain H3N2.
The research,...
Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
September 22, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
September 15, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Intranasal Seasonal...
A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference
January 28, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott...
Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus
January 07, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug...
Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season
December 16, 2013 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new...